Alpha Cognition (ACOG) announced the strategic appointments of Jen Pesa, Vice President of Commercial; Jack Kelly, Head of Market Access; ...

Alpha Cognition Inc. (Nasdaq: ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to ...

Alpha Cognition Inc. (NASDAQ:ACOG) and China Medical System Holdings Limited announced an exclusive licensing agreement for ...

Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

The agreement with China Medical System Holdings Limited is for the development, manufacturing, and commercialization of ...

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition, Inc. (Nasdaq: ACOG) (“ACI” or the “Company”), a biopharmaceutical company developing ...

Alpha Cognition (ACOG) and China Medical System announced an exclusive licensing agreement for the development, manufacturing and ...

Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders ...

Alpha Cognition licenses Zunveyl to China Medical System for $44M, covering Asia (excl. Japan), Australia, and New Zealand. ALPHA-1062 shows promise in reducing neuroinflammation and ...

Alpha Cognition (ACOG) and China Medical System announced an exclusive licensing agreement for the development, manufacturing and commercialization of Zunveyl in Asia, Australia and New Zealand.

Alpha Cognition remains on track to launch Zunveyl in the United States in Q1 2025. The company will provide a corporate update and present its Launch Strategy on January 28, 2025.